pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
PD-L1 · news · pharmadog
← back to PD-L1
News · PD-L1
56
stories
7h
Merck-Kelun ADC scores survival win in Phase 3 gastroesophageal cancer trial
biospace
7h
Merck-Kelun ADC scores survival win in Phase 3 stomach cancer trial
biospace
10d
Coherus cuts 30% of staffers, Gyre makes post-acquisition layoffs
biospace
10d
AbCellera becomes latest biotech to abandon dream of developing OX40 drug
fiercebiotech
10d
Coherus shrinks headcount 30% to narrow focus of cancer combo
fiercebiotech
22d
Genmab soars to record highs after cancer drug succeeds in key trial
biopharma dive
22d
Merck outlines 2027 as ‘another year of investment’ despite recent clinical wins
fiercebiotech
23d
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
biospace
23d
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
biospace
23d
Genmab's $8B Merus bet delivers as bispecific combo halves risk of death in phase 3
fiercebiotech
26d
ESMO: BMS’ Massacesi hails ‘very promising’ data for BioNTech-partnered PD-L1xVEGF-A drug
fiercebiotech
29d
ESMO 2026: Merck’s Kelun-partnered ADC hits the ‘Goldilocks zone,’ VP says
biospace
Oct 20, 26
Hype vs. reality: What pharma’s hottest R&D bets have actually proved
biopharma dive
Oct 19, 26
Merck/Moderna, Summit/Akeso and ADCs to headline ESMO 2026
biospace
Oct 13, 26
BioNTech mRNA cancer immunotherapy misses first objective in key study
biopharma dive
Oct 2, 26
BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
biospace
Sep 29, 26
Summit snags $2B investment from AstraZeneca, clearing financial overhang
biospace
Sep 28, 26
Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC
biospace
Sep 14, 26
Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results
biopharma dive
Sep 14, 26
Summit, BioNTech, more headline WCLC with next-gen lung cancer drugs
biospace
Sep 11, 26
FDA delays approval decision for Exelixis' tyrosine kinase inhibitor in colorectal cancer
fiercebiotech
Sep 9, 26
Solstice rises with $225M series A to advance next-gen CTLA-4 immunotherapy into phase 2
fiercebiotech
Sep 8, 26
Inhibrx’s OX40 agonist add-on beats Keytruda alone in head and neck cancer
biospace
Sep 8, 26
Inhibrx CEO says progression-free survival data leave ‘no question’ about OX40 agonist’s durability
fiercebiotech
Sep 3, 26
Summit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial—again
biospace
Sep 2, 26
Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial fails
biospace
Aug 26, 26
Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debate
fiercebiotech
Aug 17, 26
AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer
biopharma dive
Aug 17, 26
STAT+: Pharmalittle: We’re reading about an AstraZeneca setback, falling U.S. drug prices, and more
stat
Aug 17, 26
AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
biospace
← prev
page 1 of 2
next →